Understand cancer cachexia subtypes in advanced cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

The UNCOVER study is a longitudinal observational cohort enrolling up to 800 patients with unresectable or stage IV colorectal, pancreatic, or non-small cell lung cancer at Kaiser Permanente Northern California. Researchers will collect demographic, clinical, imaging, biomarker, and patient-reported data to identify distinct cachexia phenotypes and how they change over time. The goal is to link each phenotype with overall survival, functional decline, and treatment tolerance, informing earlier recognition and potential pathway-targeted approaches. The study uses biospecimens, CT imaging, EHR data, device data, and physical function assessments to characterize heterogeneity in cancer cachexia. No experimental interventions are involved; it is discovery-driven and observational.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Have a primary diagnosis of unresectable or Stage IV 1) non-small cell lung cancer (NSCLC), 2) pancreatic adenocarcinoma, or 3) colorectal cancer (CRC).

Note: Patients do not need to have cachexia to be eligible

* Plan to start first line systemic anti-cancer therapy (chemotherapy, immunotherapy, targeted therapy) in the next 6 weeks or has started first-line systemic therapy in the previous 6 weeks.

Note: Patients who received systemic anti-cancer therapy previously as part of adjuvant or neoadjuvant therapy and have since recurred are still eligible if such treatment was longer than 6 months prior to enrollment.

* Have an an Eastern Cooperative Oncology Group (ECOG) performance status of 0, 1 or 2.
* Be able to understand, speak and read English.
* Be 18 years or older

Exclusion Criteria:

* Have contraindications to physical function assessments (30-second bicep curl, Timed-Up-And-Go test, or 30-Second Sit to Stand test) per the treating provider or their designee.
* Have any planned major surgeries within the next 3 months after enrollment to the best knowledge of the investigator/treating provider or their designee.
* Have received chemotherapy or surgery for separate primary cancer within the past 3 years other than non-melanoma skin cancer.
* Be pregnant or within 6 months postpartum.

Where it's running

• Kaiser Permanente Northern California
  Pleasanton, California, United States Recruiting

Study contacts

• Study coordinator: Elizabeth M Cespedes Feliciano, ScD, SM
• Email: Elizabeth.M.Cespedes@kp.org
• Phone: (510) 414-4154

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Observational study on cancer cachexia subtypes

  This study is trying to identify different types of weight and muscle loss in patients with advanced colorectal, lung, or pancreatic cancers to help improve future treatments.

  Recruiting at 196 sites University of Rochester · Fort Smith, Arkansas and 224 other locations · NCT06073431

• CPI-613 combined with hydroxychloroquine and chemotherapy for advanced solid tumors

  This study is testing a new combination of treatments, including CPI-613 and hydroxychloroquine, to see if it can help people with advanced solid tumors that haven't improved with other chemotherapy.

  Recruiting Phase 2 Northwestern University · Chicago, Illinois · NCT05733000

• Morning versus afternoon immunotherapy for advanced or metastatic solid tumors

  This trial tests whether giving standard immune checkpoint inhibitor therapy in the morning versus the afternoon changes outcomes for adults with advanced or metastatic solid tumors.

  Recruiting Phase 4 OHSU Knight Cancer Institute · Portland, Oregon · NCT07405086

• SX-682 with Atezolizumab for advanced or metastatic NSCLC

  This phase 2 trial tests whether combining SX-682 with atezolizumab can help people with advanced, metastatic, or recurrent NSCLC who have progressed after prior treatments.

  Recruiting Phase 2 University of Washington · Seattle, Washington · NCT07322341

• GT103 plus pembrolizumab for advanced STK11‑mutant non‑small cell lung cancer

  This trial tests whether adding GT103 to pembrolizumab can help adults with advanced or metastatic STK11‑mutant non‑small cell lung cancer.

  Recruiting Phase 2 Roswell Park Cancer Institute · Buffalo, New York · NCT07017829

• Adding diclofenac to single-agent immunotherapy for metastatic non-small cell lung cancer

  This trial tests if adding the NSAID diclofenac to single‑agent PD‑1/PD‑L1 immunotherapy can help people with metastatic non‑small cell lung cancer who are showing early signs of progression.

  Recruiting at 2 sites Phase 2 Emory University · Atlanta, Georgia and 1 other locations · NCT06731270

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.